NR3C2 and atrial fibrillation: Neefs et al. demonstrated that the mineralocorticoid receptor antagonists (MRA), spironolactone, and eplerenone significantly reduce new‐onset AF and recurrent AF; MRA treatment can be considered an additive therapeutic strategy for AF.9